

Indivior Publications 2014

Manuscripts

Treatment of Schizophrenia

1. Laffont CM, Gomeni R, Heidbreder C, Fudala PJ, Nasser AF. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment. *Clin Pharmacokinet.* 2014;53(6):533-543. <http://dx.doi.org/10.1007/s40262-014-0132-7>

Treatment of Substance Use Disorder

1. Bani M, Andorn A, Heidbreder C. Pharmacologically, are smokers the same as nonsmokers? *Curr. Opin. Pharmacol.* 2014;14:42-49. <http://dx.doi.org/10.1016/j.coph.2013.11.003>

Rescue Medications

1. Liu Y, Zheng B, Strafford S, Orugunty R, Sullivan M, Gus J, Heidbreder C, Fudala PJ, Nasser A. Liquid chromatography/tandem mass spectrometry method for simultaneous determination of cocaine and its metabolite (-)ecgonine methyl ester in human acidified stabilized plasma samples. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2014;961:77-85. <http://dx.doi.org/10.1016/j.jchromb.2014.04.052>
2. Nasser A, Fudala PJ, Zheng B, Liu Y, Chen Y, Heidbreder C. A randomized, double-blind, placebo-controlled trial of RBP-8000 in cocaine abusers: Pharmacokinetic profile of RBP-8000 and cocaine and effects of RBP-8000 on cocaine-induced Physiological effects. *J Addict Dis.* 2014;33(4):289-302. <http://dx.doi.org/10.1080/10550887.2014.969603>

Treatment of Opioid Use Disorder

1. Nasser AF, Heidbreder C, Gomeni R, Fudala PJ, Zheng B, Greenwald MK. A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence. *Pharmacokinetics,* 2014;53(9):813-824. <http://dx.doi.org/10.1007/s40262-014-0155-0>

Abstracts

Treatment of Opioid Use Disorder

1. Nasser A, Heidbreder C, Fudala PJ, Sutton H, Zheng B, Greenwald MK. A model-based approach to evaluate the PK and mu-opioid receptor occupancy of RBP-6000, a once monthly depot formulation of buprenorphine. *Proceedings of the American Society for Clinical Pharmacology and Therapeutics (ASCPT).* Abstract: #14-A-113-ASCPT. Atlanta, GA; March 18-22, 2014.

Treatment of Schizophrenia

1. Gomeni R, Laffont CM, Zheng B, Heidbreder C, Fudala PJ, Nasser A. A dose-switching simulation analysis from INVEGA® SUSTENNA® (paliperidone palmitate) or RISPERDAL® CONSTA® to RBP-7000, a new sustained released formulation of risperidone. Proceedings of the American Society for Clinical Pharmacology and Therapeutics (ASCPT). Abstract: #14-A-53-ASCPT. Atlanta, GA; March 18-22, 2014.
2. Min L, Heidbreder C, Fudala PJ, Nasser A. A model-based approach to characterize risperidone release, absorption, and disposition after administration of RBP-7000 in schizophrenic patients. Proceedings of the American Society for Clinical Pharmacology and Therapeutics (ASCPT). Abstract: #14-A-115-ASCPT. Atlanta, GA; March 18-22, 2014.
3. Li, M., Heidbreder, C., Fudala, P.J., Nasser A. (2014) A model-based approach to characterize risperidone release, absorption, and disposition after administration of RBP-7000 in schizophrenic patients. Proceedings of the American Society for Clinical Pharmacology and Therapeutics (ASCPT). Atlanta, GA; March 18-22, 2014.
4. Laffont CM, Gomeni R, Zheng B, Heidbreder C, Fudala PJ, Nasser AF. Population PK modeling and simulation to support dose selection of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenic patients. Proceedings of the 23rd Meeting of the Population Approach Group in Europe (PAGE). Alicante, Spain; June 10-13, 2014.

Other

1. Zheng B, Liu Y, Heidbreder C, Fudala PJ, Nasser A. A model-based approach to predict plasma/brain cocaine levels following RBP-8000, a double mutant bacterial cocaine esterase, administration in humans. Proceedings of the American Society for Clinical Pharmacology and Therapeutics (ASCPT). Abstract: #14-A-124-ASCPT. Atlanta, GA; March 18-22, 2014.
2. Chen Y, Zheng B, Liu Y, Heidbreder C, Fudala PJ, Nasser A. A double-blind, placebo-controlled study to evaluate the effects of RBP-8000 on cocaine PK and cocaine-induced physiological effects in cocaine users. Proceedings of the American Society for Clinical Pharmacology and Therapeutics (ASCPT). Abstract: #14-A-149-ASCPT. Atlanta, GA; March 18-22, 2014.